2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 026

Treatment strategies for articular flares in JIA patients receiving biologic therapy
Abstract Number: 092

Treatment-Refractory Juvenile Idiopathic Arthritis: Clinical Features and Biologic/Targeted Synthetic DMARD Utilization Patterns in a Single-Center Cohort
Abstract Number: 128

Trends in Medicaid Enrollment Churn Among Children with Rheumatic Disease Diagnoses, 2018-2023
Abstract Number: 076

Understanding Etiology (CLUE) Study: Whole Genome Sequencing of Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 126

Unmet Social Needs in Pediatric Rheumatic Disease: A Study of Disparities
Abstract Number: 139

Unravelling the Pathogenesis of PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis and cervical Adenitis) Flares through Proteomics in the Salivary Matrix: A Potentially Non-Invasive Milieu for Biomarker Discovery
Abstract Number: 059

Use of Multimodal Teaching to Improve Resident Confidence in Evaluating Rheumatic Conditions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].